Citizens JMP raised the firm’s price target on Artivion (AORT) to $53 from $47 and keeps an Outperform rating on the shares. Artivion’s Q3 results reflected a beat and raise, as well as positive incremental product and clinical updates, the analyst tells investors in a research note. The firm continues to be impressed by Artivion’s strong fundamentals, dependable base business, complementary advanced stent graft division, and notable EBITDA growth and margin profile.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AORT:
- Artivion’s Strong Q3 Performance and Growth Prospects Justify Buy Rating
- Artivion Inc. Reports Strong Q3 2025 Financial Results
- Artivion reports Q3 non-GAAP EPS 16c, consensus 15c
- Artivion raises FY25 revenue view to $439M-$445M from $435M-$443M
- Artivion announces treatment of first patient in ARTIZEN pivotal trial